NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.



Don't have an account? Register

ADVERTISEMENT

ADVERTISEMENT

New monotherapy for multiple myeloma

By David O’Riordan - 01st Feb 2024


Reference: February 2024 | Issue 2 | Vol 10 | Page 46


The European Medicines Agency (EMA) human medicines committee (CHMP) has recommended a conditional marketing authorisation in the European Union for Elrexfio (elranatamab) as a monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies and whose cancer has worsened since they received their last treatment.

Multiple myeloma is characterised by uncontrolled proliferation of plasma cells in the bone marrow. Excess production of these plasma cells results in widespread destruction and end organ damage. Many patients present with anaemia, osteolytic bone lesions, hypercalcaemia, and kidney injury at the time of diagnosis. Approximately 380 to 400 people are diagnosed with the disorder every year in Ireland.

A range of new medicines for the treatment of multiple myeloma has been developed and approved in recent years, leading to a steady overall improvement in patient survival. However, new medicines are needed for patients who have already been treated with the three main classes of medicines (immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies) and who no longer respond to them.

Elranatamab, the active substance in Elrexfio, is a monoclonal antibody that targets two proteins simultaneously. By attaching at the same time to B-cell maturation antigen (BCMA), which is present on the surface of the multiple myeloma cells, and to CD3, a protein that is present on the T-cells, it activates the T-cells to kill the multiple myeloma cells.

Elrexfio was supported through the EMA’s PRIority MEdicines (PRIME) scheme, which provides early and enhanced scientific and regulatory support to medicines that have a particular potential to address patients’ unmet medical needs.

The CHMP based its recommendation for a conditional marketing authorisation on an open-label, single arm, multicentre, phase 2 clinical trial. The part of the trial that was considered as pivotal investigated the efficacy of Elrexfio monotherapy in 123 participants with refractory multiple myeloma who had received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, but who had not received prior BCMA-directed therapy.

Some 61 per cent of patients enrolled in the trial responded to the treatment with Elrexfio and more than 70 per cent of the responding patients have a probability to live without disease progression for an average of 15 months.

The overall safety profile of elranatamab was established by analysing data from 265 participants. The most common reported side-effects were a decrease in blood cells, infections, and cytokine release syndrome (CRS).

One of the main risks associated with elranatamab use is neurological toxicity, including immune effector cell-associated neurotoxicity (ICANS). Monitoring and mitigation strategies for CRS and ICANS are described in the product information, and in the risk management plan that is an integral part of the authorisation.

Elrexfio is recommended for a conditional marketing authorisation, one of the EU regulatory mechanisms to facilitate early access to medicines that fulfil an unmet medical need. This type of approval allows the agency to recommend a medicine for marketing authorisation with less complete data than normally expected, if the benefit of a medicine’s immediate availability to patients outweighs the risk inherent in the fact that not all the data are yet available.

In order to confirm the results obtained from the pivotal trial, the company will have to submit data from a randomised phase 3 trial comparing the efficacy and safety of elranatamab monotherapy, and elranatamab used in combination with daratumumab, versus the treatment regimen daratumumab, pomalidomide, and dexamethasone in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, but not more than three, including lenalidomide and a proteasome inhibitor. The company is also required to submit the final results of the pivotal phase 2 clinical trial.

The opinion adopted by the CHMP is an intermediary step on Elrexfio’s path to patient access. The opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation.

Once a marketing authorisation has been granted, decisions about price and reimbursement will take place at the level of each member state, taking into account the potential role or use of this medicine in the context of the national health system of that country.  

Author Bios



Leave a Reply

ADVERTISEMENT

Latest

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

Latest Issue
Update Neurology & Psychiatry

You need to be logged in to access this content. Please login or sign up using the links below.

ADVERTISEMENT

Trending

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT